Discontinued — last reported Q2 '23
CVS Health AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value decreased by 29.1% to $1.78B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 104.2%, from $871.00M to $1.78B. Over 4 years (FY 2020 to FY 2024), AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value shows an upward trend with a 71.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher values indicate a larger portion of the portfolio is sensitive to recent market interest rate increases.
The aggregate fair value of available-for-sale and trading debt securities that are currently in an unrealized loss posi...
Commonly reported by commercial banks to demonstrate the fair value impact of interest rate cycles on their balance sheet.
afs_debt_securities_unrealized_loss_less_12m_fv| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.02B | $4.24B | $6.80B | $12.50B | $15.83B | $16.97B | $14.23B | $7.37B | $7.48B | $6.50B | $1.93B | $4.58B | $6.04B | $871.00M | $7.51B | $4.87B | $2.51B | $1.78B |
| QoQ Change | — | +40.2% | +60.4% | +83.8% | +26.6% | +7.2% | -16.1% | -48.2% | +1.4% | -13.0% | -70.3% | +137.0% | +32.0% | -85.6% | +761.8% | -35.2% | -48.4% | -29.1% |
| YoY Change | — | — | — | — | +423.3% | +300.3% | +109.2% | -41.0% | -52.8% | -61.7% | -86.4% | -37.9% | -19.2% | -86.6% | +288.5% | +6.3% | -58.5% | +104.2% |